Jackson S L, Peterson G M, Vial J H, Jupe D M L
School of Pharmacy, University of Tasmania, Tasmania, Australia.
J Intern Med. 2004 Aug;256(2):137-44. doi: 10.1111/j.1365-2796.2004.01352.x.
A number of studies have reported that the risk of bleeding associated with warfarin is highest early in the course of therapy. This study examined the effect of a programme focused on the transition of newly anticoagulated patients from hospital to the community.
Open-label randomized controlled trial.
Home-based follow-up of patients discharged from acute care hospital in southern Tasmania, Australia.
A total of 128 patients initiated on warfarin in hospital and subsequently discharged to general practitioner (GP) care were enrolled in the study. Sixty were randomized to home monitoring (HM) and 68 received usual care (UC).
HM patients received a home-visit by the project pharmacist and point-of-care international normalized ratio (INR) testing on alternate days on 4 occasions, with the initial visit two days after discharge. The UC group was solely managed by the GP and only received a visit 8 days after discharge to determine anticoagulant control.
At discharge, 42% of the HM group and 45% of the UC group had a therapeutic INR. At day 8, 67% of the HM patients had a therapeutic INR, compared with 42% of UC patients (P < 0.002). In addition, 26% of UC patients had a high INR, compared with only 4% of HM patients. Bleeding events were assessed 3 months after discharge and occurred in 15% of HM patients, compared with 36% of the UC group (P < 0.01).
This programme improved the initiation of warfarin therapy and resulted in a significant decrease in haemorrhagic complications in the first 3 months of therapy.
多项研究报告称,华法林相关出血风险在治疗早期最高。本研究探讨了一项针对新接受抗凝治疗患者从医院过渡到社区的项目的效果。
开放标签随机对照试验。
对澳大利亚塔斯马尼亚州南部一家急症医院出院的患者进行家庭随访。
共有128名在医院开始使用华法林并随后出院接受全科医生(GP)护理的患者纳入研究。60名患者被随机分配至家庭监测(HM)组,68名接受常规护理(UC)。
HM组患者在出院后两天接受项目药剂师的家访,并在4次访视中每隔一天进行即时国际标准化比值(INR)检测。UC组仅由全科医生管理,仅在出院8天后接受一次访视以确定抗凝控制情况。
出院时,HM组42%的患者和UC组45%的患者INR达到治疗水平。在第8天,67%的HM组患者INR达到治疗水平,而UC组为42%(P<0.002)。此外,26%的UC组患者INR过高,而HM组仅为4%。在出院3个月后评估出血事件,HM组15%的患者发生出血,而UC组为36%(P<0.01)。
该项目改善了华法林治疗的起始情况,并在治疗的前3个月显著降低了出血并发症的发生率。